12244Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Department of Surgery, 12244Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Prog Transplant. 2022 Sep;32(3):252-260. doi: 10.1177/15269248221107039. Epub 2022 Jun 14.
Utilizing allografts from donors after cardiac death (DCD) has improved organ availability, and DCD livers comprise a growing proportion of transplantations. However, it has been suggested that DCD transplantations have worse outcomes. We aimed to characterize outcomes in a large cohort of DCD transplantations, identify trends in outcomes over time, and identify factors associated with the development of biliary complications. Design: We conducted an observational retrospective cohort study of patients receiving DCD liver allografts within a large academic teaching hospital with a high transplantation volume. Consecutive patients who underwent Type III DCD liver transplantation from 2006-2016 were included in our cohort. Re-transplantations and multi-organ transplant recipients were excluded. Ninety-six type III DCD transplantations occurred between 2006-2016. We report a 1one-year patient survival of 90.6% (87) and a 5five-year patient survival of 69.8% (67). Twenty-nine (30.2%) patients experienced any biliary complication in the first year following discharge, with 17 (17.7%) experiencing ischemic cholangiopathy. Five-year patient (P = 0.04) and graft (P = 0.005) survival improved over time. Post-operative biliary complications experienced during index admission and prior to discharge were found to be associated with the development of biliary complications (P = 0.005) and ischemic cholangiopathy (P = 0.01) following discharge. Our data suggested that outcomes using DCD allografts have improved, however biliary complications remain a significant issue in DCD transplantation. Patients who experienced post-operative biliary complications during index admission may require more frequent screening to allow the initiation of earlier treatment for biliary complications.
利用心脏死亡供体(DCD)的同种异体移植物提高了器官可用性,DCD 肝脏构成了移植的比例越来越大。然而,有人认为 DCD 移植的效果较差。我们旨在描述大型 DCD 移植队列的结果,确定随时间推移的结果趋势,并确定与胆道并发症发展相关的因素。设计:我们对在具有高移植量的大型学术教学医院中接受 DCD 肝脏同种异体移植物的患者进行了一项观察性回顾性队列研究。我们的队列包括 2006 年至 2016 年间接受 III 型 DCD 肝脏移植的连续患者。排除再次移植和多器官移植受者。2006 年至 2016 年间发生了 96 例 III 型 DCD 移植。我们报告了 1 年患者生存率为 90.6%(87),5 年患者生存率为 69.8%(67)。29 例(30.2%)患者在出院后 1 年内发生任何胆道并发症,其中 17 例(17.7%)发生缺血性胆管炎。5 年患者(P=0.04)和移植物(P=0.005)生存率随时间提高。发现住院期间和出院前经历的术后胆道并发症与出院后胆道并发症(P=0.005)和缺血性胆管炎(P=0.01)的发展相关。我们的数据表明,使用 DCD 同种异体移植物的结果已经改善,但是胆道并发症仍然是 DCD 移植中的一个重要问题。在住院期间经历术后胆道并发症的患者可能需要更频繁的筛查,以便为胆道并发症的早期治疗提供机会。